Actively Recruiting
Study on the Effectiveness of Tranilast in the Treatment of Medium to Large Volume Benign Prostatic Hyperplasia
Led by Yifeng Jing · Updated on 2026-01-08
30
Participants Needed
2
Research Sites
101 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Benign prostatic hyperplasia (BPH) is one of the most common urinary and reproductive system diseases in elderly men. The preliminary research of the research group found that mast cells are cells that promote the progression of BPH, and the commonly used mast cell membrane stabilizer and TGF - β pathway inhibitor tranilast significantly inhibited the increase in prostate volume in animal experiments, which is considered to have potential applications in the treatment of BPH. This study plans to include 30 patients with medium to large volume BPH and experimentally explore the efficacy and safety of tranilast in the treatment of medium to large volume BPH.
CONDITIONS
Official Title
Study on the Effectiveness of Tranilast in the Treatment of Medium to Large Volume Benign Prostatic Hyperplasia
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with benign prostatic hyperplasia aged 55 to 75 years old
- Prostate volume greater than 40 mL
- Urinary obstruction with an International Prostate Symptom Score (IPSS) of 8 or higher
- Maximum urinary flow rate less than 15 mL/s (not measured if catheterized)
You will not qualify if you...
- Urinary disorders caused by neurogenic diseases
- Uncontrolled acute urinary tract infections
- Lower urinary tract obstruction from causes other than BPH, such as urethral stricture
- History of radiation therapy or surgery in the lower urinary tract or pelvic area
- History or suspicion of urinary system tumors (e.g., bladder or prostate cancer)
- Current or past abnormal liver function exceeding normal limits
- Abnormal kidney function exceeding normal limits
- Current use of warfarin
- Allergy to tranilast or related drugs
- Presence of major untreated diseases like malignant tumors, autoimmune diseases, angina, heart failure, or severe respiratory or digestive illnesses
- Any other conditions deemed unsuitable by the researchers
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Shanghai General Hospital
Shanghai, Outside U.S./Canada, China, 200086
Actively Recruiting
2
Shanghai General Hospital
Shanghai, China, 200086
Not Yet Recruiting
Research Team
Y
Yifeng Jing
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here